Clinical Trials · NCT07417306
A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
- Phase
- Phase 3
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- Enrollment
- 912
- Start date
- Mar 2026
- Locations
- 1 site, China
- Primary endpoint
- Change from baseline in Hemoglobin A1c (HbA1c)